IMMUNEONCO-B (01541) has seen a surge of over 5%, currently up 5.22% at HKD 11.47, with a trading volume of HKD 40.47 million. According to recent updates from IMMUNEONCO-B, scientists Mary E. Blenko and two others have been awarded the 2025 Nobel Prize in Physiology or Medicine for their groundbreaking research in the field of peripheral immune tolerance mechanisms. This innovative research has identified the immune system's inhibitory switch, offering transformative therapies for millions of patients worldwide suffering from autoimmune diseases and cancer. Regulatory T cells (Treg cells), regulated by the Foxp3 transcription factor, maintain immune tolerance, and their dysfunction is closely linked to autoimmune diseases and cancers. Additionally, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a key effector molecule that facilitates the immunosuppressive function of Treg cells. The discovery of Treg cells and the study of their mechanisms have provided a theoretical foundation for developing a new generation of immunomodulatory drugs. IMMUNEONCO-B is actively advancing the clinical development of Tazlestobart (IMM27M), a new generation CTLA-4 antibody designed to exert antitumor effects by eliminating Treg cells from the tumor microenvironment. Tazlestobart (IMM27M) is an innovative drug developed by IMMUNEONCO-B, which enhances ADCC activity through genetic engineering, enabling comprehensive clearance of Treg cells in the tumor microenvironment. The primary mechanism of IMM27M is to target specific molecules on Treg cells, namely CTLA-4, to modulate their function or number, thereby enhancing immune responses.